Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Tells Investors to Reject Mini-Tender Offer

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said after the close of the market on Tuesday that it has received notice that private investment firm TRC Capital has made an unsolicited mini-tender offer to purchase up to 1 million shares of the company's stock at $181.75 per share in cash.

Thermo Fisher is recommending its shareholders to reject the offer. The TRC offer price is about 4.43 percent lower than the $190.17 closing price of Thermo Fisher's shares on Nov. 17, the last closing price before the offer was made. The offer is for about .249 percent of Thermo's outstanding shares of common stock as of the offer date, it added.

Shares of Thermo Fisher closed on Tuesday up about 1 percent on the New York Stock Exchange at $192.93. The company had more than 400 million shares outstanding.

Mini-tender offers seek to acquire less than 5 percent of a firm's outstanding shares, avoiding some investor protections given to larger tender offers, Thermo Fisher said, adding that TRC has made "many similar unsolicited mini-tender offers" for other publicly traded companies.

According to Thermo Fisher, the US Securities and Exchange Commission has warned investors that some bidders make tenders at below-market prices "'hoping that they will catch investors off guard if the investor do not compare the offer price to the current market price." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.